Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
NurExone Biologic: Technisches (täglich, wöchentlich, monatlich) & Analysten "Strong Buy"-Rating!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM1G | ISIN: US95075A1079 | Ticker-Symbol:
NASDAQ
28.03.24
20:39 Uhr
6,440 US-Dollar
+0,090
+1,42 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
WEREWOLF THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
WEREWOLF THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur WEREWOLF THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.03.Werewolf Therapeutics GAAP EPS of -$0.33, revenue of $1.5M1
07.03.Werewolf Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
07.03.Werewolf Therapeutics, Inc. - 10-K, Annual Report1
07.03.Werewolf Therapeutics, Inc. - 8-K, Current Report1
07.03.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update123- Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 - - WTX-124 recommended dose for expansion (RDE)...
► Artikel lesen
05.03.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 20241
09.02.Werewolf Therapeutics, Inc. - 8-K, Current Report-
08.01.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook271- Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 - - WTX-124: updated interim monotherapy dose-escalation...
► Artikel lesen
04.01.Werewolf Therapeutics, Inc. - 8-K, Current Report1
04.01.Werewolf Therapeutics, Inc.: Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors188WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
► Artikel lesen
22.11.23Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference1
14.11.23Werewolf Therapeutics, Inc. - 8-K, Current Report-
14.11.23Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update221- Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity...
► Artikel lesen
03.11.23Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?5
03.11.23Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars3
03.11.23Werewolf Therapeutics rises on early-stage data for lead drug3
03.11.23Werewolf Therapeutics, Inc. - 8-K, Current Report1
03.11.23Werewolf Therapeutics, Inc.: Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting3
31.10.23Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting2
10.08.23Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update552- Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1